Top ▲

keratoconjunctivitis sicca

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:1203
Name:keratoconjunctivitis sicca
Associated with:0 target
2 immuno-relevant ligands
Synonyms
dry eye disease | KCS | keratitis sicca
Description
A dry eye syndrome characterised by a deficiency of aqueous tear film over the ocular surface; symptoms include inflammation of the cornea and surrounding tissues from drying, which can lead to damage of the ocular surface. and visual disturbance.
Database Links
Disease Ontology: DOID:12895

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols

No target related data available for keratoconjunctivitis sicca

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
lifitegrast
Immuno Disease Comments: Approved drug for keratoconjunctivitis sicca.
Clinical Use: Lifitegrast is a topical integrin antagonist approved by the US FDA (July 2016) for the treatment of keratoconjunctivitis sicca (dry eye disease) [3-4].
Phase 3 trial results are published in [3]. | View clinical data
Bioactivity Comments: No specific binding data are provided in [4] to substantiate the lifitegrast/LFA-1 interaction. Target engagement is inferred from biological assays showing inhibition of T cell adhesion and inhibition of inflammatory mediator secretion. In in vitro assays, lifitegrast inhibits Jurkat T cell and HuT 78 T cell adhesion to immobilised ICAM-Ig with IC50s of 2.98nM and 9nM respectively [4].
Lifitegrast was designed to have minimal systemic exposure, to limit action at sites other than at the site of administration [2]. | View biological activity
navamepent
Immuno Disease Comments: Phase 2 clinical trials NCT00799552 and NCT01675570 are completed.
Clinical Use: Phase 2 trials in dry eye syndrome (keratoconjunctivitis sicca), allergic conjunctivitis, and inflammation and pain following cataract surgery have been completed. | View clinical data
Bioactivity Comments: Bioactivity with respect to effects on occular tissues and occular inflammation in model animals is reported in US20140275247A1, but no target interaction is specified [1]. | View biological activity

References

Show »

1. Gjorstrup P, Schwartz CE. (2016) Compositions and methods for the treatment of inflammation. Patent number: US20140275247A1. Assignee: ANIDA PHARMA Inc. Priority date: 13/04/2013. Publication date: 19/04/2016.

2. Newman M, Hunke W. (2014) Lfa-1 inhibitor formulations. Patent number: WO2014100135. Assignee: Sarcode Bioscience Inc.. Priority date: 19/12/2012. Publication date: 26/06/2014.

3. Sheppard JD, Torkildsen GL, Lonsdale JD, D'Ambrosio Jr FA, McLaurin EB, Eiferman RA, Kennedy KS, Semba CP, OPUS-1 Study Group. (2014) Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study. Ophthalmology, 121 (2): 475-83. [PMID:24289915]

4. Zhong M, Gadek TR, Bui M, Shen W, Burnier J, Barr KJ, Hanan EJ, Oslob JD, Yu CH, Zhu J et al.. (2012) Discovery and Development of Potent LFA-1/ICAM-1 Antagonist SAR 1118 as an Ophthalmic Solution for Treating Dry Eye. ACS Med Chem Lett, 3 (3): 203-6. [PMID:24900456]